A Phase 3 interventional study of Oral Lenacapavir (LEN) and F/TDF in Pre-Exposure Prophylaxis of HIV Infection, sponsored by Gilead Sciences. Active, not recruiting at 93 sites in 8 countries. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in HIV Infections by Gilead Sciences — 2 open to participants now, 8 under way, 4 of them phase 3. HIV Infections · Gilead Sciences.
Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 2nd largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2021, is one of 26 in phase 3, and was the 78th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →2 of the 84 studies in HIV Infections by Gilead Sciences are open now, in 3 countries. Recruiting first, the newest first:
Gilead Sciences · Sites in United States, Australia, Japan
Ages 18+
Gilead Sciences · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 16 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 21 · Phase 3 30 · Phase 4 12
First in 1999; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,292 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 131 across the 72 interventional studies, 476 across the 5 observational. Of the 71 that completed or were terminated, 28 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 84 studies in HIV Infections by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection.
The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.
Key Inclusion Criteria:
Incidence Phase
Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:
Randomized Phase
Key Exclusion Criteria:
Incidence Phase
Randomized Phase
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the following for up to approximately 52 weeks: * Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks * Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily * Oral LEN 600 mg on Days 1 and 2 Participants will receive oral LEN if SC injections are not available.
Drug: Oral Lenacapavir (LEN) · Drug: Sub-cutaneous (SC) Lenacapavir (LEN) · Drug: PTM F/TDF
Participants will receive the following for up to approximately 52 weeks: * SC LEN placebo every 26 weeks * Oral F/TDF 200/300 mg once daily * PTM Oral LEN on Days 1 and 2 Participants will receive oral LEN placebo if SC injections are not available.
Drug: F/TDF · Drug: Placebo SC LEN · Drug: PTM Oral LEN
Participants will be offered entry into LEN OLE Phase, following completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase. Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days). Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2. All participants in LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first. After completing LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an early study drug discontinuation (ESDD), be referred to local PrEP services if needed, and have a 30-day follow-up visit.
Drug: Oral Lenacapavir (LEN) · Drug: Sub-cutaneous (SC) Lenacapavir (LEN)
Participants who prematurely discontinue study drug during the Randomized Blinded Phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days). Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit.
Drug: F/TDF · Drug: F/TAF (for US participants only)
Tablets administered orally without regard to food
Also known as: GS-6207
Tablets administered orally
Also known as: Truvada®
Administered via SC injections
Also known as: GS-6207; Yeztugo
Administered via SC injections
Tablets administered orally
Tablets administered orally
Drug page: Emtricitabine tenofovir alafenamide
F/TAF tablets administered orally once daily
Also known as: Descovy
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was \> 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit: * Positive HIV-1/2 differentiation Ab, OR * Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR * HIV-1 RNA quantitative test ≥200 copies/mL.
Time frame: Incidence Phase Screening Visit (Day 1)
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)
HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.
Time frame: Up to 149 weeks
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF
HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.
Time frame: Up to 149 weeks
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.
Time frame: Up to 149 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug.
Time frame: First dose date up to 184 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.
Time frame: First dose date up to 184 weeks
4807 participants were screened. Out of 4807, 4634 had at least 1 non-missing HIV-1 diagnosis based on HIV test results from a central laboratory. So, 4634 participants were considered for screening in Incidence Phase and were included in All Screened Set. Out of 4634, 3292 were enrolled and randomized in Randomized Blinded Phase. Incidence Phase refers to Screening Phase. Participants were enrolled in Argentina, Brazil, Mexico, Peru, Puerto Rico, South Africa, Thailand and the United States.
| Milestone | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF | Open-Label Extension (OLE) Phase: LEN | OLE Phase: F/TDF |
|---|---|---|---|---|
| Started | 2195 | 1097 | 0 | 0 |
| Completed | 1808 | 906 | 0 | 0 |
| Not completed | 387 | 191 | 0 | 0 |
| Withdrew: Lost to follow-up | 178 | 78 | 0 | 0 |
| Withdrew: Withdrew consent | 152 | 73 | 0 | 0 |
| Withdrew: Randomized but never treated | 12 | 9 | 0 | 0 |
| Withdrew: Hiv-1 infection | 6 | 11 | 0 | 0 |
| Withdrew: Investigator's discretion | 19 | 8 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 8 | 5 | 0 | 0 |
| Withdrew: Adverse event | 6 | 2 | 0 | 0 |
| Withdrew: Death | 5 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 3 | 0 | 0 |
| Milestone | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF | Open-Label Extension (OLE) Phase: LEN | OLE Phase: F/TDF |
|---|---|---|---|---|
| Started | 0 | 0 | 1797 | 863 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1797 | 863 |
bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was \> 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit: * Positive HIV-1/2 differentiation Ab, OR * Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR * HIV-1 RNA quantitative test ≥200 copies/mL.
| HIV-1 events per 100 person-years | Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis |
|---|---|
| Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) | 2.374 (1.649 to 3.417) |
HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.
| HIV-1 events per 100 person-years | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis |
|---|---|---|
| Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set) | 0.103 (0.012 to 0.373) | 2.374 (1.649 to 3.417) |
HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.
| HIV-1 events per 100 person-years | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF |
|---|---|---|
| Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF | 0.103 (0.012 to 0.373) | 0.931 (0.426 to 1.768) |
A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.
| HIV-1 events per 100 person-years | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF |
|---|---|
| Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN | 0.125 (0.015 to 0.452) |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug.
| percentage of participants | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF |
|---|---|---|
| Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 94.5 | 91.6 |
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.
| percentage of participants | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF |
|---|---|---|
| Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities | 15.0 | 16.5 |
Collected over All-Cause Mortality: Up to 223 weeks; Adverse Events: Up to 184 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | 5/2,195 (0.2%) | 96/2,183 (4.4%) | 1,950/2,183 (89.3%) |
| Randomized Blinded Phase: Placebo LEN + F/TDF | 2/1,097 (0.2%) | 56/1,088 (5.1%) | 905/1,088 (83.2%) |
| Event | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF |
|---|---|---|
| AppendicitisInfections and infestations | 7/2183 | 6/1088 |
| Suicide attemptPsychiatric disorders | 11/2183 | 4/1088 |
| Suicidal ideationPsychiatric disorders | 3/2183 | 5/1088 |
| AnxietyPsychiatric disorders | 0/2183 | 3/1088 |
| Hepatitis AInfections and infestations | 5/2183 | 1/1088 |
| Major depressionPsychiatric disorders | 1/2183 | 2/1088 |
| Acute myocardial infarctionCardiac disorders | 3/2183 | 0/1088 |
| PneumoniaInfections and infestations | 3/2183 | 1/1088 |
| DepressionPsychiatric disorders | 3/2183 | 1/1088 |
| VertigoEar and labyrinth disorders | 0/2183 | 1/1088 |
| Event | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF |
|---|---|---|
| Injection site noduleGeneral disorders | 1432/2183 | 443/1088 |
| Injection site painGeneral disorders | 1299/2183 | 609/1088 |
| Injection site erythemaGeneral disorders | 394/2183 | 218/1088 |
| Injection site indurationGeneral disorders | 362/2183 | 115/1088 |
| Anal chlamydia infectionInfections and infestations | 351/2183 | 156/1088 |
| Oropharyngeal gonococcal infectionInfections and infestations | 344/2183 | 143/1088 |
| Anal gonococcal infectionInfections and infestations | 288/2183 | 124/1088 |
| Injection site swellingGeneral disorders | 155/2183 | 105/1088 |
| Upper respiratory tract infectionInfections and infestations | 169/2183 | 90/1088 |
| DiarrhoeaGastrointestinal disorders | 161/2183 | 83/1088 |
The Randomized Blinded Phase Safety Analysis Set included all participants who took at least 1 dose of any study drug.
| Age, Continuous(years) | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF | Total |
|---|---|---|---|
| Mean | 30 ± 8.7 | 31 ± 9.5 | 30 ± 9.0 |
| Age, Customized(Participants) | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF | Total |
|---|---|---|---|
| 16 to <18 years | 3 | 1 | 4 |
| 18 to ≤ 25 years | 749 | 343 | 1092 |
| > 25 to < 35 years | 912 | 423 | 1335 |
| 35 to < 50 years | 454 | 267 | 721 |
| ≥ 50 years | 65 | 54 | 119 |
| Sex: Female, Male(Participants) | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF | Total |
|---|---|---|---|
| Female | 43 | 24 | 67 |
| Male | 2140 | 1064 | 3204 |
| Race/Ethnicity, Customized(Participants) | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF | Total |
|---|---|---|---|
| Race — White | 723 | 344 | 1067 |
| Race — Black or African American | 583 | 301 | 884 |
| Race — Other or More Than One Race | 578 | 285 | 863 |
| Race — Asian | 269 | 144 | 413 |
| Race — American Indian or Alaska Native | 19 | 12 | 31 |
| Race — Not Collected | 8 | 2 | 10 |
| Race — Native Hawaiian or Other Pacific Islander | 3 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 1378 | 675 | 2053 |
| Ethnicity — Not Hispanic or Latino | 804 | 413 | 1217 |
| Ethnicity — Not Collected | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF | Randomized Blinded Phase: Placebo LEN + F/TDF | Total |
|---|---|---|---|
| Puerto Rico | 9 | 2 | 11 |
| Argentina | 161 | 64 | 225 |
| United States | 431 | 233 | 664 |
| Brazil | 769 | 396 | 1165 |
| South Africa | 246 | 112 | 358 |
| Mexico | 8 | 4 | 12 |
| Thailand | 250 | 139 | 389 |
| Peru | 309 | 138 | 447 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Aug 2024, 37 months.
Results were first posted in Sep 2025, 1 year after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 37 months is above that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenacapavir · Emtricitabine tenofovir alafenamide